# Zoetis

Cytopoint, Apoquel, Vaccines — Recombinant mAbs, viral vectors.

Source: https://en.bioecon.ru/companies/zoetis/
Updated: 2026-06-25

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $9.5 billion (2025) | https://s203.q4cdn.com/620628704/files/doc_presentations/2026/04/IR-Zoetis-Corporate-Overview-April-2026.pdf, https://s203.q4cdn.com/620628704/files/doc_presentations/2026/06/updated/IR-Zoetis-Corporate-Overview.pdf, https://www.zoetis.com/our-company/our-story/zoetis-at-a-glance |
| Headcount | approximately 14,500 employees worldwide | https://s203.q4cdn.com/620628704/files/doc_presentations/2026/04/IR-Zoetis-Corporate-Overview-April-2026.pdf, https://s203.q4cdn.com/620628704/files/doc_presentations/2026/06/updated/IR-Zoetis-Corporate-Overview.pdf, https://www.sec.gov/Archives/edgar/data/1555280/000130817926000228/zts015237-ars.pdf, https://www.zoetis.com/our-company/our-story/zoetis-at-a-glance |
| Production site | 21 to 23 manufacturing sites globally, including sites in the U.S. (Kalamazoo, Lincoln, Durham, Buellton, Union City, Atlanta), Ireland, Belgium, Spain, Italy, Brazil, Australia, New Zealand, and China | https://s203.q4cdn.com/620628704/files/doc_presentations/2026/04/IR-Zoetis-Corporate-Overview-April-2026.pdf, https://s203.q4cdn.com/620628704/files/doc_presentations/2026/06/updated/IR-Zoetis-Corporate-Overview.pdf, https://www.zoetis.com/products-and-science/manufacturing-supply |
| Capacity | Zoetis has expanded capacity for monoclonal antibodies (mAbs) at its Tullamore, Ireland site and is investing $590 million in a new mAb and vaccine facility in Georgia, U.S. | https://news.zoetis.com/press-releases/press-release-details/2021/Zoetis-to-Expand-its-Manufacturing-Capability-in-Tullamore-Ireland/default.aspx |
| Regulatory approval | Key products like Apoquel, Cytopoint, and various recombinant vector vaccines (e.g., Poulvac Procerta line) have received regulatory approvals from bodies such as the FDA (U.S.) and USDA (U.S.), as well as international authorities like the EMA and others for various indications and geographic markets | https://investor.zoetis.com/news/news-details/2026/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx, https://www.keypedia.com/records/eir/zoetis-belgium-sa/2c5d1500-a520-4966-b1e8-47a824797482, https://www.sec.gov/Archives/edgar/data/1555280/000130817926000228/zts015237-ars.pdf, https://www.sec.gov/Archives/edgar/data/1555280/000155528023000074/zts-20221231.htm, https://www.vmd.defra.gov.uk/register/good-manufacturing-practice/cerficate/VMDGMP/M240/2026, https://www.zoetis.com/products-and-science/manufacturing-supply |
| Certification | Zoetis facilities maintain global regulatory compliance, including Good Manufacturing Practice (GMP) certifications from authorities such as the VMD (UK) and FDA (U.S.) for pharmaceuticals and biologics production | https://www.vmd.defra.gov.uk/register/good-manufacturing-practice/cerficate/VMDGMP/M240/2026, https://www.zoetis.com/products-and-science/manufacturing-supply |

Independent sources: keypedia.com, s203.q4cdn.com, sec.gov, vmd.defra.gov.uk

## Technologies

- [One Health — zoonosis & AMR monitoring as a service](https://en.bioecon.ru/technology/one-health-zoonosis-amr-monitoring/)
- [Veterinary biotech & mRNA veterinary drugs](https://en.bioecon.ru/technology/veterinary-biotech-mrna-drugs/)
- [Veterinary genomics & companion-animal diagnostics](https://en.bioecon.ru/technology/veterinary-genomics-companion-animal-diagnostics/)